@misc{indiciaef8a08ec8d6b5,
  title = {The FDA-approved CDK4/6 inhibitor Abemaciclib is a potent agonist of the β-arrestin-biased atypical chemokine receptor ACKR3},
  author = {Buzink, M. C. M. L. and Darcis, J. and Nesheva, D. and Meyrath, M. and Jenjak, S. and Banerjee, N. and Ganguly, M. and Reyaz, A. and Banerjee, R. and Leliveld, E. A. and Kwon, Y.-J. and Paggetti, J. and Zielhuis, S. and Pluim, D. and Huitema, A. and Volkman, B. F. and Vischer, H. F. and Shukla, A. K. and Chevigne, A. and Szpakowska, M. and Leurs, R.},
  year = {2026},
  doi = {10.64898/2026.11.03.764001},
  url = {https://www.biorxiv.org/content/10.64898/2026.11.03.764001v1},
  note = {Source identifier: 10.64898/2026.11.03.764001}
}